Dear Editor:

The article by Chakraborty *et al*. about the relationship between down-regulation of osteopontin and breast tumour progression *in vivo*is highly interesting \[[@b1]\]. Recent studies indicate a close association between not only breast cancer and osteopontin but other systemic malignancies as well. Studies over the past few years have especially shown a strong relationship between osteopontin expression and oral carcinogenesis.

For instance, Devoll *et al*. in a recent study have reported that nearly 67% of oral squamous cell carcinomas and nearly 54% of all oral carcinomas *in situ* lesions are immunoreactive for osteopontin \[[@b2]\]. Similarly, a recent study by Matsuzaki *et al*. suggests that osteo-pontin may be an important marker of early invasion in lingular squamous cell carcinomas \[[@b3]\]. In fact, tumours of the tongue that overexpress osteopontin are usually more aggressive and carry a worse prognosis \[[@b4]\]. It has also been shown that osteopontin expression is increased in salivary gland tumours especially in polymorphous low-grade adenocarcinomas and pleomorphic adenomas \[[@b5]\]. More recently, antisense oligonucleotides have been used to inhibit tumerogenesis in oral cancer cell lines further confirming the pathological role of osteopontin in oral carcinogenesis \[[@b6]\].

Besides oral malignancies, osteopontin has also been implicated in the etio-pathogenesis of numerous other systemic malignancies such as non-small cell lung cancers and breast cancers \[[@b7]\]. Clearly, osteopontin has a major role to play in the development and growth of oral malignancies. Research studies should focus on osteopontin as a possible target molecule for the development of strategies and therapies to control oral cancers.
